Examination of the neurofilament light chain in the blood of patients with multiple sclerosis

Česká verzia

Authors: P. Turčáni ¹; M. Vítková ²
Authors place of work: I. neurologická klinika LF UK a UN Bratislava, Slovensko ¹; Neurologická klinika LF UPJŠ a UNLP Košice, Slovensko ²
Published in the journal: Cesk Slov Neurol N 2023; 86(4): 286-287
Category:
doi: https://doi.org/10.48095/cccsnn2023286

Zdroje

1. Fialová L, Nosková L, Kalousová M et al. Analytické a preanalytické aspekty stanovení lehkých řetězců neurofilament v biologických tekutinách. Cesk Slov Neurol N 2022; 85/118 (1): 11–16. doi: 10.48095/ccsnn202211.

2. Benkert P, Meier S, Schaedelin S et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022; 21 (3): 246–257. doi: 10.1016/S1474-4422 (22) 00009-6.

3. Berger T, Adamczyk-Sowa M, Csépány T et al. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Ther Adv Neurol Disord 2020; 13: 175628642097522. doi: 10.1177/1756286420975223.

4. Bittner S, Oh J, Havrdová EK et al. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 2021; 144 (10): 2954–2963. doi: 10.1093/brain/awab241.

5. Filippi P, Vestenická V, Siarnik P et al. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis. Neuro Endocrinol Lett 2020; 41 (1): 17–26.

6. Kapoor R, Smith KE, Allegretta M et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology 2020; 95 (10): 436–444. doi: 10.1212/WNL.0000000000010346.

7. Szilasiová J, Rosenberger J, Fedičová M et al. Neurofilament light chain levels are associated with disease activity determined by no evident disease activity in multiple sclerosis patients. Eur Neurol 2021; 84 (4): 272–279. doi: 10.1159/000515806